Literature DB >> 1656608

Characterization of Rous sarcoma virus intronic sequences that negatively regulate splicing.

M T McNally1, R R Gontarek, K Beemon.   

Abstract

Retroviruses splice only a fraction of their primary RNA transcripts to subgenomic mRNA. The unspliced RNA is transported to the cytoplasm, where it serves as genomic RNA as well as mRNA for the gag and pol genes. Deletion of sequences from the Rous sarcoma virus gag gene, which is part of the intron of the subgenomic mRNAs, was previously observed to result in an increase in the ratio of spliced to unspliced RNA. These sequences, which we termed a negative regulator of splicing (NRS), can be moved to the intron of a heterologous gene resulting in an accumulation of unspliced RNA in the nucleus. We have used such constructs, assayed by transient expression in chicken embryo fibroblasts, to define the minimal sequences necessary to inhibit splicing. Maximal NRS activity was observed with a 300-nt fragment containing RSV nts 707-1006; two noncontiguous domains within this fragment, one of which contains a polypyrimidine tract, were both found to be essential. The NRS element was active exclusively in the sense orientation in two heterologous introns tested and in both avian and mammalian cells. Position dependence was also observed, with highest activity when the NRS was inserted in the intron near the 5' splice site. The NRS element was also active at an exon position 136 nts upstream of the 5' splice site but not at sites further upstream. In addition, it did not affect the splicing of a downstream intron.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656608     DOI: 10.1016/0042-6822(91)90758-4

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  49 in total

1.  Point mutations in the avian sarcoma/leukosis virus 3' untranslated region result in a packaging defect.

Authors:  J M Aschoff; D Foster; J M Coffin
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  The role of overlapping U1 and U11 5' splice site sequences in a negative regulator of splicing.

Authors:  C S Hibbert; R R Gontarek; K L Beemon
Journal:  RNA       Date:  1999-03       Impact factor: 4.942

3.  Retroviral splicing suppressor requires three nonconsensus uridines in a 5' splice site-like sequence.

Authors:  R E Paca; C S Hibbert; C T O'Sullivan; K L Beemon
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Map of cis-acting sequences that determine alternative pre-mRNA processing in the E3 complex transcription unit of adenovirus.

Authors:  H A Brady; A Scaria; W S Wold
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

5.  Solution structure of the pseudo-5' splice site of a retroviral splicing suppressor.

Authors:  Javier Cabello-Villegas; Keith E Giles; Ana Maria Soto; Ping Yu; Annie Mougin; Karen L Beemon; Yun-Xing Wang
Journal:  RNA       Date:  2004-09       Impact factor: 4.942

6.  Retroviral splicing suppressor sequesters a 3' splice site in a 50S aberrant splicing complex.

Authors:  Keith E Giles; Karen L Beemon
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

7.  Efficient polyadenylation of Rous sarcoma virus RNA requires the negative regulator of splicing element.

Authors:  Brent L Fogel; Lisa M McNally; Mark T McNally
Journal:  Nucleic Acids Res       Date:  2002-02-01       Impact factor: 16.971

8.  A secondary structure that contains the 5' and 3' splice sites suppresses splicing of duck hepatitis B virus pregenomic RNA.

Authors:  Daniel D Loeb; Amanda A Mack; Ru Tian
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Splice site selection in polyomavirus late pre-mRNA processing.

Authors:  D B Batt; L M Rapp; G G Carmichael
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Selection and characterization of replication-competent revertants of a Rous sarcoma virus src gene oversplicing mutant.

Authors:  L Zhang; S B Simpson; C M Stoltzfus
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.